INTRODUCTION: In the present study, we examined the levels of the pro-inflammatory cytokine IL-18 and its natural inhibitor, the IL-18 binding protein (IL-18BP), in sera of Wegener's granulomatosis (WG) patients at various stages of the disease. PATIENTS AND METHODS: Sera from eight consecutive biopsy-proven systemic WG patients (four men and four women; age at diagnosis 58.4 +/- 13.8 years) were obtained longitudinally with a follow-up period of 55.2 +/- 30 months. Sera obtained from 50 healthy subjects were used as controls. RESULTS AND DISCUSSION: Serum levels of IL-18, IL-18BP, and free IL-18 obtained during an active phase of the disease (Birmingham Vasculitis Activity Score, BVAS > 10) were more than twofold higher than levels in the same patients during inactive disease stages (BVAS < 5; P < 0.002; P < 0.006, and P < 0.03 for IL-18, IL-18BP, and free IL-18, respectively). During inactive stages, the levels of these markers were comparable to those of healthy controls. The elevated levels of IL-18 and IL-18BP in sera during active stages of disease suggest a possible role in the pathogenesis and course of the WG. CONCLUSION: Despite the elevated IL-18BP levels during active disease, free IL-18 remained higher than in the inactive disease stages, suggesting a potential benefit of administration of exogenous IL-18BP as a novel therapeutic approach for active WG.
INTRODUCTION: In the present study, we examined the levels of the pro-inflammatory cytokine IL-18 and its natural inhibitor, the IL-18 binding protein (IL-18BP), in sera of Wegener's granulomatosis (WG) patients at various stages of the disease. PATIENTS AND METHODS: Sera from eight consecutive biopsy-proven systemic WG patients (four men and four women; age at diagnosis 58.4 +/- 13.8 years) were obtained longitudinally with a follow-up period of 55.2 +/- 30 months. Sera obtained from 50 healthy subjects were used as controls. RESULTS AND DISCUSSION: Serum levels of IL-18, IL-18BP, and free IL-18 obtained during an active phase of the disease (Birmingham Vasculitis Activity Score, BVAS > 10) were more than twofold higher than levels in the same patients during inactive disease stages (BVAS < 5; P < 0.002; P < 0.006, and P < 0.03 for IL-18, IL-18BP, and free IL-18, respectively). During inactive stages, the levels of these markers were comparable to those of healthy controls. The elevated levels of IL-18 and IL-18BP in sera during active stages of disease suggest a possible role in the pathogenesis and course of the WG. CONCLUSION: Despite the elevated IL-18BP levels during active disease, free IL-18 remained higher than in the inactive disease stages, suggesting a potential benefit of administration of exogenous IL-18BP as a novel therapeutic approach for active WG.
Authors: J Paulukat; M Bosmann; M Nold; S Garkisch; H Kämpfer; S Frank; J Raedle; S Zeuzem; J Pfeilschifter; H Mühl Journal: J Immunol Date: 2001-12-15 Impact factor: 5.422
Authors: P Lamprecht; G Kumanovics; A Mueller; E Csernok; A Komocsi; A Trabandt; W L Gross; A Schnabel Journal: Clin Exp Immunol Date: 2002-04 Impact factor: 4.330
Authors: S H Kim; M Eisenstein; L Reznikov; G Fantuzzi; D Novick; M Rubinstein; C A Dinarello Journal: Proc Natl Acad Sci U S A Date: 2000-02-01 Impact factor: 11.205
Authors: Joseph R Maxwell; Rajwardhan Yadav; Robert J Rossi; Carl E Ruby; Andrew D Weinberg; Hector L Aguila; Anthony T Vella Journal: J Immunol Date: 2006-07-01 Impact factor: 5.422
Authors: C Plater-Zyberk; L A Joosten; M M Helsen; P Sattonnet-Roche; C Siegfried; S Alouani; F A van De Loo; P Graber; S Aloni; R Cirillo; E Lubberts; C A Dinarello; W B van Den Berg; Y Chvatchko Journal: J Clin Invest Date: 2001-12 Impact factor: 14.808
Authors: Steven T Leach; Isabella Messina; Daniel A Lemberg; Daniela Novick; Menachem Rubenstein; Andrew S Day Journal: Inflamm Bowel Dis Date: 2008-01 Impact factor: 5.325
Authors: Paul A Monach; Roscoe L Warner; Gunnar Tomasson; Ulrich Specks; John H Stone; Linna Ding; Fernando C Fervenza; Barri J Fessler; Gary S Hoffman; David Iklé; Cees G M Kallenberg; Jeffrey Krischer; Carol A Langford; Mark Mueller; Philip Seo; E William St Clair; Robert Spiera; Nadia Tchao; Steven R Ytterberg; Kent J Johnson; Peter A Merkel Journal: Ann Rheum Dis Date: 2012-09-12 Impact factor: 19.103
Authors: Marie-Claude Durpès; Catherine Morin; Judith Paquin-Veillet; Raphaël Beland; Martin Paré; Marie-Odile Guimond; Mark Rekhter; George L King; Pedro Geraldes Journal: Cardiovasc Res Date: 2015-03-24 Impact factor: 10.787
Authors: Claudia A Nold-Petry; Thomas Lehrnbecher; Andrea Jarisch; Dirk Schwabe; Josef M Pfeilschifter; Heiko Muhl; Marcel F Nold Journal: PLoS One Date: 2010-01-13 Impact factor: 3.240
Authors: Marie Altendahl; Pauline Maillard; Danielle Harvey; Devyn Cotter; Samantha Walters; Amy Wolf; Baljeet Singh; Visesha Kakarla; Ida Azizkhanian; Sunil A Sheth; Guanxi Xiao; Emily Fox; Michelle You; Mei Leng; David Elashoff; Joel H Kramer; Charlie Decarli; Fanny Elahi; Jason D Hinman Journal: PLoS One Date: 2020-01-24 Impact factor: 3.240